European NeoAg Summit 2019

3rd Annual European NeoAg Summit: Supercharging Cell Immunotherapies & Cancer Vaccines is organized by Hanson Wade and will be held from Apr 23 - 25, 2019 at Amsterdam Marriott Hotel, Amsterdam, Noord Holland, Netherlands.

Description:

The Summit is the leading industry-dedicated meeting focused on advancing personalized cancer immunotherapy through neoantigen targeting.

Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into space means that tumor-specific antigen targeting is set to explode.

At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss:
• Reducing the discordance between various neoantigen prediction methods
• Maximizing the immune response to neoantigens
• Shortening the needle-to-needle time of personalized cancer immunotherapy
• Navigating the evolving regulatory landscape to faster approval

Join the leaders from BioNTech, Genentech, Genocea, Gritstone Oncology, Agenus, Ziopharm, Vaccibody, the European Medicines Agency and many more to spur on more efficacious personalized cancer vaccines and cell therapies.

FOCUS DAY-Tue 23rd Apr

Spotlight Workshop A:
Neoantigen Identification to Ensure Immunogenic & Clinically Relevant Neoantigens
Workshop Leader: Michal Bassani-Sternberg

Join this workshop to learn and discuss:
• Key advances in in silico MHC ligand prediction through mass spectrometry data
• Minimizing time and cost of the neoantigen selection, prediction and validation process
• Challenges and improvements in predicting the T-cell reponse

Spotlight Workshop B:
Regulatory Pathway & Landscape for Neoantigen-based Cancer Immunotherapy
Workshop Leader: Asterios Tsiftsoglou

In this workshop, attendees will learn and discuss:
• Current regulatory requirements in the clinical development and manufacturing of neoantigen based cancer immunotherapy
• Requirements to demonstrate convincing efficacy in neoantigen targeting
• What are the key considerations to take into account when working with regulatory body?

Prices:

Conference + 2 Workshops: EUR 3397.0,
Conference + 1 Workshop: EUR 2898.0,
Conference only: EUR 2399.0,
Workshop Only (Each): EUR 599.0

Speakers: John Castle, Associate Vice President, Head of Translational Medicine and Bioinformatics, Agenus, Andrew Ishizuka, Chief Scientific Officer, Avidea Technologies, Mathias Vormehr, Head of Cancer Vaccines, BioNTech, Michal Bassani-Sternberg, Sternberg Director, Immunopeptidomics Unit Center of Experimental Therapeutics, CHUV, Asterios Tsiftsoglou, Committee for Advanced Therapies Member, European Medicines Agency, Lélia Delamarre, Senior Scientist, Cancer Immunology Research, Genentech, Jessica Flechtner, Chief Scientific Officer, Genocea, Jennifer Busby, Senior Director of Mass Spectrometry and Proteomics, Gritstone Oncology, Norbert Hilf, Director of Translational Development, Immatics, John Wang, Chief Executive Officer, IOVaxis, Trevor Clancy, Chief Scientific Officer, OncoImmunity, Sean Boyle, Director, Bioinformatics Applications, Personalis, Agnete Fredriksen, Chief Scientific Officer, Vaccibody, Laurence Cooper, Chief Executive Officer, Ziopharm, Hans Keirstead, Chief Executive Officer, AIVITA Biomedical, Michael Stein, Executive Chairman, Valo Therapeutics, Anna Pasetto, Assistant Professor, Karolinska Institutet

Time: 8:00 am - 5:00 pm